Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Oct;177(10):1350-1360.
doi: 10.7326/M24-0080. Epub 2024 Sep 3.

Comparative Performance of Common Fecal Immunochemical Tests : A Cross-Sectional Study

Affiliations
Comparative Study

Comparative Performance of Common Fecal Immunochemical Tests : A Cross-Sectional Study

Barcey T Levy et al. Ann Intern Med. 2024 Oct.

Abstract

Background: Despite widespread use of fecal immunochemical tests (FITs) for colorectal cancer (CRC) screening, data to guide test selection are limited.

Objective: To compare the performance characteristics of 5 commonly used FITs, using colonoscopy as the reference standard.

Design: Cross-sectional study. (ClinicalTrials.gov: NCT03264898).

Setting: Three U.S. academic medical centers and affiliated endoscopy units.

Participants: Patients aged 50 to 85 years undergoing screening or surveillance colonoscopy.

Intervention: Participants completed 5 different FITs before their colonoscopy, including 4 qualitative tests (Hemoccult ICT, Hemosure iFOB, OC-Light S FIT, QuickVue iFOB) and 1 quantitative test (OC-Auto FIT, which was run at the manufacturer's threshold for positivity of >100 ng/mL).

Measurements: The primary outcome was test performance (sensitivity and specificity) for each of the 5 FITs for advanced colorectal neoplasia (ACN), defined as advanced polyps or CRC. Positivity rates, positive and negative predictive values, and rates of unevaluable tests were compared. Multivariable models were used to identify factors affecting sensitivity.

Results: A total of 3761 participants were enrolled, with a mean age of 62.1 years (SD, 7.8); 63.2% of participants were female, 5.7% were Black, 86.4% were White, and 28.7% were Hispanic. There were 320 participants with ACN (8.5%), including 9 with CRC (0.2%). The test positivity rate varied 4-fold (3.9% to 16.4%) across FITs. Rates of unevaluable FITs ranged from 0.2% to 2.5%. The sensitivity for ACN varied from 10.1% to 36.7%, and specificity varied from 85.5% to 96.6%. Differences in sensitivity between FITs were all statistically significantly different except between Hemosure iFOB and QuickVue iFOB, and specificity differences were all statistically significantly different from one another. In addition to FIT brand, distal location of ACN was also associated with higher FIT sensitivity.

Limitation: The study did not assess the programmatic sensitivity of annual FIT.

Conclusion: Although considered a single class, FITs have varying test performance for detecting ACN and should not be considered interchangeable.

Primary funding source: National Institutes of Health.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M24-0080.

Figures

Figure 1.
Figure 1.. Flowchart of participants.
FIT = fecal immunochemical test; HQ = health questionnaire.
Figure 2.
Figure 2.. Test performance of 5 qualitative FITs for advanced colorectal neoplasia.
Error bars indicate 95% CIs. FIT = fecal immunochemical test; NPV = negative predictive value; PPV = positive predictive value.

References

    1. GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7:627–647. doi: 10.1016/S2468-1253(22)00044-9 - DOI - PMC - PubMed
    1. Lin JS, Perdue LA, Henrikson NB, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325:1978–1998. doi: 10.1001/jama.2021.4417 - DOI - PubMed
    1. Davidson KW, Barry MJ, Mangione CM, et al. ; U.S. Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:1965–1977. doi: 10.1001/jama.2021.6238 - DOI - PubMed
    1. Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116:458–479. doi: 10.14309/ajg.0000000000001122 - DOI - PubMed
    1. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250–281. doi: 10.3322/caac.21457 - DOI - PubMed

Associated data

LinkOut - more resources